Genmab AS (GMAB)
20.65
+0.18
(+0.88%)
USD |
NASDAQ |
Nov 22, 16:00
20.92
+0.27
(+1.31%)
After-Hours: 20:00
Genmab Revenue (Quarterly): 816.44M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 816.44M |
| June 30, 2024 | 779.75M |
| March 31, 2024 | 603.46M |
| December 31, 2023 | 686.83M |
| September 30, 2023 | 688.11M |
| June 30, 2023 | 609.32M |
| March 31, 2023 | 408.70M |
| December 31, 2022 | 706.18M |
| September 30, 2022 | 553.31M |
| June 30, 2022 | 452.67M |
| March 31, 2022 | 319.65M |
| December 31, 2021 | 392.83M |
| September 30, 2021 | 366.23M |
| June 30, 2021 | 319.59M |
| March 31, 2021 | 256.29M |
| December 31, 2020 | 327.42M |
| September 30, 2020 | 270.83M |
| June 30, 2020 | 805.00M |
| March 31, 2020 | 131.69M |
| December 31, 2019 | 438.95M |
| September 30, 2019 | 154.93M |
| June 30, 2019 | 116.45M |
| March 31, 2019 | 89.95M |
| December 31, 2018 | 188.92M |
| September 30, 2018 | 93.35M |
| Date | Value |
|---|---|
| June 30, 2018 | 81.67M |
| March 31, 2018 | 112.35M |
| December 31, 2017 | 160.99M |
| September 30, 2017 | 51.12M |
| June 30, 2017 | 114.35M |
| March 31, 2017 | 35.93M |
| December 31, 2016 | 134.48M |
| September 30, 2016 | 54.68M |
| June 30, 2016 | 53.72M |
| March 31, 2016 | 25.16M |
| December 31, 2015 | 84.27M |
| September 30, 2015 | 41.37M |
| June 30, 2015 | 25.74M |
| March 31, 2015 | 16.17M |
| December 31, 2014 | 36.21M |
| September 30, 2014 | 48.28M |
| June 30, 2014 | 21.31M |
| March 31, 2014 | 45.36M |
| December 31, 2013 | 39.42M |
| September 30, 2013 | 26.60M |
| June 30, 2013 | 24.19M |
| March 31, 2013 | 28.28M |
| December 31, 2012 | 28.36M |
| September 30, 2012 | 19.45M |
| June 30, 2012 | 19.28M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
131.69M
Minimum
Mar 2020
816.44M
Maximum
Sep 2024
496.66M
Average
445.81M
Median
Revenue (Quarterly) Benchmarks
| Novo Nordisk AS | 10.51B |
| Ascendis Pharma AS | 63.61M |
| Galecto Inc | -- |
| Evaxion Biotech AS | 3.017M |
| IO Biotech Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 186.57M |
| Total Expenses (Quarterly) | 504.16M |
| EPS Diluted (Quarterly) | 0.2919 |
| Enterprise Value | 10.52B |
| Gross Profit Margin (Quarterly) | 95.07% |
| Profit Margin (Quarterly) | 22.85% |
| Earnings Yield | 5.10% |
| Operating Earnings Yield | 7.02% |
| Normalized Earnings Yield | 5.759 |